A Plus Biotech Business Summary

A Plus Biotech (6918.TW) is a leading Taiwanese medical device manufacturer specializing in orthopedic trauma and reconstructive implants, generating revenue through the design, production, and wholesale of its proprietary "Aplus" brand products and the distribution of third-party biochemical agents. The company’s business is structured into three primary segments: Trauma Fixation (anatomical bone plates, screws, and intramedullary nails), Precision Surgical Products (3D-printed patient-specific instruments and knee preservation systems), and Agency/Proxy Products (artificial bone, PRP, and hemostatic powders). A Plus distinguishes itself in the Asia-Pacific market by utilizing localized clinical data to engineer implants with "Asian Curvature" specifications, offering superior anatomical fit compared to Western-designed templates. Its primary competitors include global industry leaders such as Stryker, DePuy Synthes (Johnson & Johnson), and Zimmer Biomet, as well as domestic peer United Orthopedic Corporation. Within this competitive landscape, A Plus holds a dominant position in Taiwan’s self-pay locking plate market with a market share exceeding 30%. The company was founded in 2009 by a leadership team with deep expertise in the orthopedic medical device sector, currently led by Chairman Li Si-Ming and General Manager (CEO) Luo Xiang-Wei. Under their tenure, A Plus transitioned from a local distributor to an R&D-driven manufacturer, successfully listing on the Taiwan Stock Exchange (Mainboard) in June 2025. The executive team is further bolstered by Chief Scientist Dr. Luo Zhu-An, who spearheads the integration of 3D imaging and biomechanical engineering into the company’s surgical planning platforms, and CFO Ke Pei-Jun. The Board of Directors includes strategic representation from institutional investors such as He-Ming Investment and Wei-Kai International, reflecting strong backing from the Taiwanese financial and medical communities. This leadership group has focused on aggressive international expansion, securing regulatory approvals across Southeast Asia, China, and Japan to establish A Plus as a regional leader in precision orthopedic solutions.